PT  - JOURNAL ARTICLE
AU  - GARYPHALLIA POULAKOU
AU  - EVANGELOS DIMAKAKOS
AU  - ANASTASIOS KOLLIAS
AU  - KONSTANTINOS G. KYRIAKOULIS
AU  - VASILIKI RAPTI
AU  - IOANNIS TRONTZAS
AU  - CHARALAMPOS THANOS
AU  - MAHMOUD ABDELRASOUL
AU  - THEODORA VANTANA
AU  - KONSTANTINOS LEONTIS
AU  - ELENI KAKALOU
AU  - KATERINA ARGYRAKI
AU  - IOANNIS BARABOUTIS
AU  - EVANGELOS MICHELAKIS
AU  - EVANGELOS GIAMARELLOS-BOURBOULIS
AU  - KATERINA DIMAKOU
AU  - GEORGIOS TSOUKALAS
AU  - ANGELIKI RAPTI
AU  - EVANGELOS D. MICHELAKIS
AU  - KONSTANTINOS N. SYRIGOS
TI  - Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study
AID  - 10.21873/invivo.12305
DP  - 2021 Jan 01
TA  - In Vivo
PG  - 653--661
VI  - 35
IP  - 1
4099  - http://iv.iiarjournals.org/content/35/1/653.short
4100  - http://iv.iiarjournals.org/content/35/1/653.full
SO  - In Vivo2021 Jan 01; 35
AB  - Background/Aim: To investigate the efficacy (prognosis, coagulation/inflammation biomarkers) and safety (bleeding events) of different anticoagulation dosages in COVID-19 inpatients. Patients and Methods: COVID-19 inpatients (Athens, Greece) were included. The “Enhanced dose THRomboprophylaxis in Admissions (ETHRA)” protocol was applied in certain Departments, suggesting the use of intermediate anticoagulation dosage. The primary endpoint was a composite of intubation/venous thromboembolism/death. Inflammation/coagulation parameters were assessed. Results: Among 127 admissions, 95 fulfilled the inclusion criteria. Twenty-one events (4 deaths, 17 intubations) were observed. Regression analysis demonstrated significant reduction of events with intermediate or therapeutic dosage [HR=0.16 (95%CI=0.05-0.52) p=0.002; HR=0.17 (0.04-0.71) p=0.015, respectively]. D-Dimer values were higher in those who met the composite endpoint. Intermediate dosage treatment was associated with decreased values of ferritin. Three patients (3%) had minor hemorrhagic complications. Conclusion: Anticoagulation treatment (particularly intermediate dosage) appears to have positive impact on COVID-19 inpatients’ prognosis by inhibiting both coagulation and inflammatory cascades.